Advances in Transcatheter Aortic Valve Replacement

Kleiman, Neal S.; Reardon, Michael J.

doi:10.14797/mdcj-12-1-33

Cited by 10 publications

(15 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years new and interesting TAVI devices have been implemented into clinical practice with many more being currently under the evaluation process (Table 2) [24][25][26][27][28]. The coming years will show if they become breakthroughs in transcatheter treatment of aortic valves.…”

Section: New Designs and Solutionsmentioning

confidence: 99%

State-of-the-art of transcatheter treatment of aortic valve stenosis and the overview of the InFlow project aiming at developing the first Polish TAVI system

et al. 2017

View full text Add to dashboard Cite

Initial experience of transcatheter aortic valve implantation (TAVI) or replacement (TAVR) has ap-peared as a promising minimally invasive technology for patients disqualified from surgical treatment (SAVR). Safety and efficacy of TAVI has been analyzed and assessed through numerous registries and trials. Furthermore, results obtained from comparative TAVI vs. SAVR trials proved that both treat¬ments can be considered equal in terms of post-procedural mortality and morbidity in high-risk, as well as lower risk patients. However, there are still some issues that have to be addressed, such as higher chance of paravalvular leakage, vascular injuries, conduction disturbances, malpositioning and the yet unmet problem of insufficient biological valves durability. Recent technological developments along with the learning curve of operators prove a great potential for improvement of TAVI and a chance of surpassing SAVR in various groups of patients in the near future. In pursuit of finding new solutions, the CardValve Consortium consisting of leading scientific and research institutions in Poland has been created. Under the name of InFlow and financial support from the National Center for Research and Development, they have started a project with the aim to design, create and implement into clinical practice the first, Polish, low-profile TAVI valve system, utilizing not only biological but also artificial, polymeric-based prosthesis. This review focuses on current developments in TAVI technologies including the InFlow project.

show abstract

Section: New Designs and Solutionsmentioning

confidence: 99%

State-of-the-art of transcatheter treatment of aortic valve stenosis and the overview of the InFlow project aiming at developing the first Polish TAVI system

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The Medtronic CoreValve (MCV) (Medtronic, Santa Clara, CA) is approved for treatment of patients with aortic stenosis that are at prohibitive, high, or intermediate risk for open surgery . Several factors such as valve perimeter, calcium score of the valve leaflet and annulus, and valve oversizing have consistently been associated with the risk of PVL after implantation . In a study by Sherif et al, the angle between the aorta and LVOT was also shown to be a predictor of PVL .…”

Section: Introductionmentioning

confidence: 99%

“…factors such as valve perimeter, calcium score of the valve leaflet and annulus, and valve oversizing have consistently been associated with the risk of PVL after implantation. 5,12 In a study by Sherif et al, the angle between the aorta and LVOT was also shown to be a predictor of PVL. 13 However, these factors are either features of patient anatomy or valve selection and cannot be modified easily.…”

mentioning

confidence: 98%

Optimal positioning of self‐expanding valves before deployment decreases paravalvular regurgitation following transcatheter aortic valve replacement

Dadu

Rehman

et al. 2018

Cathet Cardio Intervent

Self Cite

View full text Add to dashboard Cite

show abstract

“…Since that time, more than 250,000 procedures have been done worldwide. More important, we have developed one of the most robust datasets in our field to support this procedure, which we have summarized previously [3]. Transcatheter aortic valve replacement is now approved and commercially available for extremely high risk, high risk, and intermediate risk patients.…”

mentioning

confidence: 99%